But, in the US, the NIH-backed Activ-2 trial shuts down an arm studying an SAB antibody, and tells Synairgen to hold tight.
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
But other small biotechs are more advanced and still hope to play a role in the pandemic.
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
It's official: dramatic share price jumps in response to clinical data have become more common.